# CG Oncology, Inc.

Summary updated: 2026-10-02T15:42:30.769865Z
Canonical: https://finbar.com/research/companies/cg-oncology-inc

## Overview

CG Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer, particularly high- and intermediate-risk non-muscle-invasive bladder cancer. Its lead investigational candidate, cretostimogene grenadenorepvec, is an oncolytic immunotherapy intended to attack cancer cells and stimulate an anti-tumor immune response; it is being studied in Phase 3 and Phase 2 programs and is not an approved product. [1](https://app.finbar.com/go?id=P53564465)[2](https://app.finbar.com/go?id=P119008555)[3](https://app.finbar.com/go?id=P97832655)[4](https://app.finbar.com/go?id=P47221123)

The company’s stated mission is to develop bladder-sparing therapeutics for people with bladder cancer, with a vision centered on dignity and quality of life for people affected by urologic cancers. [5](https://cgoncology.com/careers/) CG Oncology is building U.S. commercial capabilities and has licensing arrangements covering markets outside the United States. [6](https://app.finbar.com/go?id=P29760096)[7](https://app.finbar.com/go?id=P2572601)

As a scale indicator, CG Oncology reported 142 employees at December 31, 2025. For the six months ended June 30, 2026, it reported $2.240 million in total revenue, primarily classified as commercial and development revenue. [8](https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498)[9](https://app.finbar.com/go?id=T16902607)
[1](https://app.finbar.com/go?id=P53564465)[2](https://app.finbar.com/go?id=P119008555)[3](https://app.finbar.com/go?id=P97832655)[4](https://app.finbar.com/go?id=P47221123)[5](https://cgoncology.com/careers/)[6](https://app.finbar.com/go?id=P29760096)[7](https://app.finbar.com/go?id=P2572601)[8](https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498)[9](https://app.finbar.com/go?id=T16902607)[5](https://cgoncology.com/careers/)[8](https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498)

## Products & services

CG Oncology’s lead product candidate is cretostimogene grenadenorepvec, an investigational intravesical oncolytic immunotherapy for bladder cancer. It is an engineered, replication-competent adenovirus: its E2F-1 promoter is designed to favor replication and lysis in tumor cells with Rb–E2F pathway alterations, while an encoded GM-CSF gene is intended to stimulate anti-tumor immunity. [10](https://app.finbar.com/go?id=P117659139)[11](https://app.finbar.com/go?id=P47969137)[12](https://cgoncology.com/pipeline/)

Cretostimogene is being evaluated in high-risk, BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including as monotherapy in the Phase 3 BOND-003 study, and as adjuvant therapy after tumor resection for intermediate-risk NMIBC in Phase 3 PIVOT-006. The Phase 2 CORE-008 program includes BCG-naïve and BCG-exposed cohorts, as well as a cohort combining cretostimogene with gemcitabine. [13](https://app.finbar.com/go?id=P147679845)[14](https://app.finbar.com/go?id=P147679847)[15](https://app.finbar.com/go?id=P147679848)

The company does not identify a separate marketed-product or commercial-services portfolio, and reported no revenue from cretostimogene product sales through June 30, 2026. Its disclosed Kissei license concerns development and commercialization of cretostimogene with DDM in specified Asian territories; Kissei is responsible for commercialization there, and CG Oncology supplies the licensed product. No product-sales or product-performance percentage is disclosed. [16](https://app.finbar.com/go?id=P147679970)[17](https://app.finbar.com/go?id=P147679744)
[10](https://app.finbar.com/go?id=P117659139)[11](https://app.finbar.com/go?id=P47969137)[12](https://cgoncology.com/pipeline/)[13](https://app.finbar.com/go?id=P147679845)[14](https://app.finbar.com/go?id=P147679847)[15](https://app.finbar.com/go?id=P147679848)[16](https://app.finbar.com/go?id=P147679970)[17](https://app.finbar.com/go?id=P147679744)[12](https://cgoncology.com/pipeline/)

## Geographic presence

CG Oncology’s current contact page lists its corporate headquarters in Dallas, Texas. Its 2025 year-end filing identified Irvine, California, as the principal executive office and said a Dallas office lease would begin in 2026. The filing also lists leased offices in Emeryville, California, and Branchburg, New Jersey, as well as an office/manufacturing/warehouse lease whose location is not specified in the cited disclosure. [18](https://cgoncology.com/contact/)[19](https://app.finbar.com/go?id=P82693982)

The company has reported a global clinical-trial footprint: its BOND-003 Cohort C Phase 3 trial included participants in North America, Australia, and Asia-Pacific. [20](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003) The 2026 Q2 report does not provide geographic revenue or asset figures, and no employee distribution by location was identified in the reviewed disclosures. [21](https://app.finbar.com/go?id=P147679761)
[19](https://app.finbar.com/go?id=P82693982)[21](https://app.finbar.com/go?id=P147679761)[18](https://cgoncology.com/contact/)[20](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)

## Business segments

CG Oncology reports one operating segment: the consolidated company, with no separately reported product, therapeutic-area, or geographic segments. The CEO, as chief operating decision maker, assesses performance and allocates resources using consolidated financial information; segment assets are not reviewed. The single segment therefore represents 100% of the reported business, but the company does not disclose segment-level revenue or asset contributions. [21](https://app.finbar.com/go?id=P147679761)[22](https://app.finbar.com/go?id=P59147757) Its development work includes cretostimogene for bladder-cancer indications, including non-muscle-invasive bladder cancer; this is a business focus, not a separate reportable segment. [23](https://app.finbar.com/go?id=P104907045)
[21](https://app.finbar.com/go?id=P147679761)[22](https://app.finbar.com/go?id=P59147757)[23](https://app.finbar.com/go?id=P104907045)

## Company history

CG Oncology was founded in California as Cold Genesys, Inc. on September 24, 2010. In 2014, it announced Series A financing to support development of CG0070, its investigational bladder-cancer therapy. [24](https://app.finbar.com/go?id=P164330910)[25](https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase)

The company reincorporated in Delaware in 2017 and adopted the name CG Oncology, Inc. in 2020; that year it also announced a regional licensing and commercialization agreement with Kissei for CG0070. [24](https://app.finbar.com/go?id=P164330910)[26](https://cgoncology.com/news-media/cg-oncology-announces-9/) It advanced the therapy into Phase 3 trials, reporting BOND-003 enrollment completion in 2023 and receiving FDA Fast Track and Breakthrough Therapy designations for cretostimogene in December of that year. [27](https://cgoncology.com/news-media/cg-oncology-completes/)[28](https://cgoncology.com/news-media/cg-oncology-receives/)

In January 2024, CG Oncology completed its initial public offering, raising $437 million gross. It continued expanding clinical development that year, including initiating Phase 2 CORE-008 Cohort A and reporting topline BOND-003 results in December. [29](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full)[30](https://app.finbar.com/go?id=P164330892)[31](https://app.finbar.com/go?id=P164330870)
[24](https://app.finbar.com/go?id=P164330910)[30](https://app.finbar.com/go?id=P164330892)[31](https://app.finbar.com/go?id=P164330870)[25](https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase)[26](https://cgoncology.com/news-media/cg-oncology-announces-9/)[27](https://cgoncology.com/news-media/cg-oncology-completes/)[28](https://cgoncology.com/news-media/cg-oncology-receives/)[29](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full)

## Sources

1. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P53564465)
2. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P119008555)
3. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P97832655)
4. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P47221123)
5. [cgoncology.com](https://cgoncology.com/careers/)
6. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P29760096)
7. [CG Oncology, Inc. — Full financial report (2026 Q 1)](https://app.finbar.com/go?id=P2572601)
8. [ir.cgoncology.com](https://ir.cgoncology.com/sec-filings/sec-filing/10-k/0001193125-26-079498)
9. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16902607)
10. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P117659139)
11. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P47969137)
12. [cgoncology.com](https://cgoncology.com/pipeline/)
13. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147679845)
14. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147679847)
15. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147679848)
16. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147679970)
17. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147679744)
18. [cgoncology.com](https://cgoncology.com/contact/)
19. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P82693982)
20. [ir.cgoncology.com](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-publication-pivotal-phase-3-bond-003)
21. [CG Oncology, Inc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P147679761)
22. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P59147757)
23. [CG Oncology, Inc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P104907045)
24. [CG Oncology, Inc. — Ipo (2024 O)](https://app.finbar.com/go?id=P164330910)
25. [ir.cgoncology.com](https://ir.cgoncology.com/news-releases/news-release-details/1357-million-series-round-financing-accelerate-its-ongoing-phase)
26. [cgoncology.com](https://cgoncology.com/news-media/cg-oncology-announces-9/)
27. [cgoncology.com](https://cgoncology.com/news-media/cg-oncology-completes/)
28. [cgoncology.com](https://cgoncology.com/news-media/cg-oncology-receives/)
29. [ir.cgoncology.com](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-closing-initial-public-offering-and-full)
30. [CG Oncology, Inc. — Ipo (2024 O)](https://app.finbar.com/go?id=P164330892)
31. [CG Oncology, Inc. — Ipo (2024 O)](https://app.finbar.com/go?id=P164330870)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.